175 related articles for article (PubMed ID: 31054986)
1. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
3. Cardiac and renal AL amyloidosis controlled by autologous stem cell transplantation for 17 years accompanying late onset atrial fibrillation and complete atrioventricular block.
Iijima T; Sawa N; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Ubara Y; Ohashi K
CEN Case Rep; 2023 Nov; 12(4):362-367. PubMed ID: 36795309
[TBL] [Abstract][Full Text] [Related]
4. Cardiac and autologous stem cell transplantation hematopoietic in patients with AL amyloidosis.
Carretero M; Villanueva E; Brulc EB; Faelo FM; Aguirre MA; Pérez-de-Arenaza D; Belziti CA; Arbelbide JA; Nucifora EM; Posadas-Martinez ML
Arch Cardiol Mex; 2023; 93(4):435-441. PubMed ID: 37972368
[TBL] [Abstract][Full Text] [Related]
5. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
D'Souza A; Dispenzieri A; Wirk B; Zhang MJ; Huang J; Gertz MA; Kyle RA; Kumar S; Comenzo RL; Peter Gale R; Lazarus HM; Savani BN; Cornell RF; Weiss BM; Vogl DT; Freytes CO; Scott EC; Landau HJ; Moreb JS; Costa LJ; Ramanathan M; Callander NS; Kamble RT; Olsson RF; Ganguly S; Nishihori T; Kindwall-Keller TL; Wood WA; Mark TM; Hari P
J Clin Oncol; 2015 Nov; 33(32):3741-9. PubMed ID: 26371138
[TBL] [Abstract][Full Text] [Related]
6. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
[TBL] [Abstract][Full Text] [Related]
7. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
[TBL] [Abstract][Full Text] [Related]
8. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.
Zhang Y; Guo J; Chen W; Zhao L; Huang X
Bone Marrow Transplant; 2024 Mar; 59(3):350-358. PubMed ID: 38148411
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Left Ventricular
Clerc OF; Datar Y; Cuddy SA; Bianchi G; Taylor A; Benz DC; Robertson M; Kijewski MF; Jerosch-Herold M; Kwong RY; Ruberg FL; Liao R; Di Carli MF; Falk RH; Dorbala S
medRxiv; 2023 Sep; ():. PubMed ID: 37745589
[TBL] [Abstract][Full Text] [Related]
12. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation.
D'Souza A; Huang J; Hari P
Biol Blood Marrow Transplant; 2016 Apr; 22(4):768-770. PubMed ID: 26743343
[TBL] [Abstract][Full Text] [Related]
13. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T
ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090
[TBL] [Abstract][Full Text] [Related]
14. [Recommendations for the treatment of AL amyloidosis].
Brulc EB; Carretero M; Aguirre MA; Negro A; Ulacia MD; Perez de Arenaza D; Villanueva E; Sáez MS; Sorroche P; Posadas Martínez ML; Nucifora EM
Medicina (B Aires); 2022; 82(4):591-604. PubMed ID: 35904916
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.
Bal S; Estrada-Merly N; Costa LJ; Qazilbash MH; Kumar S; D'Souza A
Blood Cancer J; 2023 Nov; 13(1):170. PubMed ID: 37968258
[No Abstract] [Full Text] [Related]
16. AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238501
[TBL] [Abstract][Full Text] [Related]
17. Emerging therapy in light-chain and acquired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation.
Di Nora C; Sponga S; Ferrara V; Patriarca F; Fanin R; Nalli C; Lechiancole A; Vendramin I; Livi U
J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):261-267. PubMed ID: 33633041
[TBL] [Abstract][Full Text] [Related]
18. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
19. Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis.
Briasoulis A; Bampatsias D; Petropoulos I; Rempakos A; Patras R; Theodorakakou F; Makris N; Dimopoulos MA; Stamatelopoulos K; Kastritis E
Eur Heart J Cardiovasc Imaging; 2024 Apr; 25(5):698-707. PubMed ID: 38142437
[TBL] [Abstract][Full Text] [Related]
20. Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.
Lacouture Fierro JA; Ribero Vargas DA; Sánchez Cano J; Gaviria Jaramillo LM; Perilla Suarez OG; Galvez Cárdenas KM; Ospina Ospina S
Colomb Med (Cali); 2023; 54(3):e2025667. PubMed ID: 38107838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]